BeiGene stock gains 18% on first day

By Jonathan Breen
04 Feb 2016

The stock of Chinese biopharmaceutical company BeiGene has shot up 18% on its first day of trading on the Nasdaq.

The drugmaker sold 6.6m American Depositary Shares at $24 each on Tuesday evening in the US, a day earlier than planned. Lead underwriters and joint bookrunners Cowen & Co, Goldman Sachs and Morgan Stanley marketed the offering at $22-$24 each.

Following strong demand, the company decided ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial